DiaMedica Therapeutics Inc.

Good morning, ladies and gentlemen, and welcome to the Diametica Therapeutics second quarter 2024 conference call. An audio recording of the webcast will be available shortly after the call today on Diametica's website at www.diametica.com in the investor relations section. Before Diametica proceeds with its remarks, please note that the company will be making forward-looking statements on today's call. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these statements. More information, including factors that could cause actual results to differ from projected results, appears in the section entitled Cautionary Statement Note Regarding Forward-Looking Statements in the company's press release issued yesterday. And under the heading Risk Factors in Diomedica's Most Recent Annual Report on Form 10-K and the Second Quarter Report on Form 10-Q, Diomedica's SEC filings are available at www.sec.gov and on its website. Please also note that any comments made on today's call speak only as of today, August 8, 2024, and may no longer be accurate at the time of any replay or transcript rereading. Diomedica disclaims any duty to update its forward-looking statements. Following the prepared remarks, we will open the phone lines for questions. I would now like to introduce your host for today's call, Mr. Rick Pauls, DietMedica's President and Chief Executive Officer. Mr. Pauls, you may begin.

Thank you, Operator. Hello, everyone, and welcome to our second quarter conference call. I am joined this morning by Dr. Lorianne Masuoka, our Chief Medical Officer, and Scott Kellan, our Chief Financial Officer. We continue to make progress on our Remedy 2 trial, and we believe we're on track for the interim analysis. The level of interest from sites and potential investigators remains high, and we will likely have to turn down some of the sites. I am grateful to our entire team. Everyone is working tirelessly to engage the highest quality research sites and facilitate their participation in the Remedy2 trial. Let me turn you over to Lorianne for a brief update on our stroke program.

Thanks, Rick. Let me start by echoing Rick's comments. We are making solid progress with our site activation activities, and we are gaining a much-welcomed momentum for the Remedy2 trial. Moving sites through the startup process continues to be very challenging. We believe this is due to the effects of continued staffing shortages at research hospitals. We believe that much of the momentum gain is related to increasingly using our people to lead direct communications with the study sites. Many sites have already noted their appreciation for the responsiveness and clarity in being able to deal directly with Diomedica personnel. As a result, we're seeing more rapid responses from both existing sites and sites working through the startup process. As part of building this momentum, we have identified 15 sites which we believe have the highest potential to rapidly enroll, meaning the ability to enroll multiple participants each month. We have prioritized recruiting and engaging these 15 sites. By the end of this quarter, we expect to have at least nine of those 15 sites active. For perspective, just 15 sites enrolling 1.6 participants each month would get us to our interim analysis enrollment within six months. As part of our ongoing engagement with study sites, we held a meeting of principal investigators and study coordinators on July 18th. The purpose of the meeting was to begin to establish a dialogue amongst the study teams and compare notes on their experiences and build some friendly competition between the study teams. At this meeting, we had a tremendous dialogue with our clinical research teams, getting their thoughts on a variety of sticking points in both the site activation and participant enrollment processes. We continue to work on mitigating or eliminating impediments to increase efficiencies and ensure that study sites feel well supported. I will now turn the call back over to Rick.